Bulk Inquiry
CDN1163
- Soluble in DMSO
- MF: C20H20N2O2
- MW: 320.39
Description
CDN1163 is an allosteric activator of sarco/endoplasmic reticulum Ca2+-ATPase 2b (SERCA2b) and markedly lowered fasting blood glucose, improved glucose tolerance, and ameliorated hepatosteatosis in a genetic model of insulin resistance and type 2 diabetes (ob/ob mice). CDN1163 treatment significantly reduced the hepatic expression of genes involved in gluconeogenesis and lipogenesis, attenuated ER stress response and ER stress-induced apoptosis, and improved mitochondrial biogenesis. Moreover, CDN1163 increased ER calcium content, rescued neurons from ER stress-induced cell death in vitro, and showed significant efficacy in the rat 6-hydroxydopamine (6-OHDA) model of Parkinson's disease.
More Information
| Parent CAS No. | 892711-75-0 |
|---|---|
| Chemical Name | 4-Isopropoxy-N-(2-methylquinolin-8-yl)benzamide |
| SMILES | C12C=CC(C)=NC1=C(NC(=O)C1C=CC(OC(C)C)=CC=1)C=CC=2 |
| MFCD | MFCD07177494 |
| InChi | InChI=1S/C20H20N2O2/c1-13(2)24-17-11-9-16(10-12-17)20(23)22-18-6-4-5-15-8-7-14(3)21-19(15)18/h4-13H,1-3H3,(H,22,23) |
| InChiKey | GVGVYDCVFBGALZ-UHFFFAOYSA-N |
| CID | 16016585 |
| Short Description | SERCA activator |
References
- S Kang et al. Small Molecular Allosteric Activator of the Sarco/Endoplasmic Reticulum Ca2+-ATPase (SERCA) Attenuates Diabetes and Metabolic Disorders. J Biol Chem. 2016 Mar 4;291(10):5185-98.
- R Dahl. A new target for Parkinson's disease: Small molecule SERCA activator CDN1163 ameliorates dyskinesia in 6-OHDA-lesioned rats. Bioorg Med Chem. 2017 Jan 1;25(1):53-57.
Other Categories
Are you sure you would like to remove this item from the shopping cart?
This item is a part of the approved quote. Removing it will remove all quote items from the cart.